News

We are heading to Vienna for the EASL Congress together with the European Association for the Study of the Liver!

We’re happy to yet again be exhibiting at the face-to-face #EASLcongress with EASL | The Home of Hepatology! We are happy to yet again be an industry partner for the biggest liver event in Europe!

The latest in hepatology is happening 📅 21–24 June.
🤝 Join us at the highlight of the year! Register today, and lets meet and discuss liver biomarkers at our booth.

Learn how to combine the use of FIB-4 together with the M30 Apoptosense® ELISA to asses hepatic fibrosis in NAFLD already at primary care!

As NAFLD global prevalence is at a record high, and continuing to increase, there is a great need to non-invasively assess patients at risk of developing NASH and fibrosis already at primary care.

By using Non-Invasive Tests to evaluate risk group patients already at primary care, only the patients at highest risk of disease progression and liver related complications  will proceed to a specialist in secondary care for further investigation. 

FIB-4 has shown to be a valuable tool to exclude advanced fibrosis, and is widely recommended  in clinical guidelines to be used. The combination of the M30 Apoptosense® ELISA with FIB-4 could enable a more reliable identification of patients with increased risk of progressed NAFLD and might be helpful for deciding which patient should be referred to a specialist and considered for liver biopsy.

Hence, in accordance with the German Society of Gastroenterology, Digestive and Metabolic Diseases Guidelines, a diagnostic tree incorporating FIB-4 and M30® is recommended for the use in NAFLD suspect patients at primary care.

Click here to access the Diagnostic Tree!

NASH and all its complications are especially prevalent in patients with severe obesity and type 2 diabetes. Yet few study data exist on biomarker performance within this patient group, in order to move away from the necessity of liver biopsy in clinical practice.

Sami Qadri, MD & Hannele Yki-Järvinen, MD et al. performed a study to evaluate the use of the M30 Apoptosense ELISA® to diagnose NASH or fibrotic NASH in an obese cohort.

They found that plasma levels of M30® associated with the full histological spectrum of NASH and also had a good ability to identify both NASH and fibrotic NASH with high sensitivity and specificity!

Click here to access the full White Paper!

🚌 We’re aboard the bus to London for a face-to-face ILC2022 with EASL | The Home of Hepatology! We are happy to yet again be an industry partner for the biggest liver event in Europe!

The latest in hepatology is happening 📅 22–26 June.
🤝 Join us at the highlight of the year! Register today, and lets meet and discuss liver biomarkers at our booth.

• M30 Apoptosense® ELISA in detecting NAFLD

• – What is NAFLD and what is the role of K18 in NAFLD?
• – How can the M30® aid in staging NAFLD and detecting NASH?
• – How can M30® incorporating biomarker scores help in detecting fibrotic NASH?

Click here to access the full brochure!